Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Medicus Pharma Ltd.MDCX · Entity 7770 | Director | June 03, 2026 | June 04, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Medicus Pharma Ltd.
Report date June 03, 2026 · Filed June 04, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $0.36 · Expires 2031-06-03 | Direct | 50,000 |
Reported balance
After 2026-06-03 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-06-03 · Grant · Acquired 50,000 · Balance 50,000 F1: The option was granted on June 3, 2026. The option is scheduled to vest quarterly in four equal installments over one year. |
Filing footnotes · ownership attribution and instrument terms
F1: The option was granted on June 3, 2026. The option is scheduled to vest quarterly in four equal installments over one year.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| June 03, 2026 Filed Jun 4, 2026 20:11 UTC | Medicus Pharma Ltd. MDCX · Entity 7770 | GrantStock Option (right to buy) · Derivative | 50,000 | $0.00 Strike: $0.36 | $0.00 |
DisclosureSEC source: 0000950142-26-001637 · es260786889_4-kaiser.xml · derivative · entry 1 Kaiser Larry · CIK 0002048184 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 50,000 Underlying: Common Shares · 50,000 shares Expires 2031-06-03 F1 · derivative.exercise_date: The option was granted on June 3, 2026. The option is scheduled to vest quarterly in four equal installments over one year. Read SEC document |
| March 30, 2026 Filed Apr 1, 2026 23:12 UTC | Medicus Pharma Ltd. MDCX · Entity 7770 | GrantStock Option (right to buy) · Derivative | 25,000 | $0.00 Strike: $0.50 | $0.00 |
DisclosureSEC source: 0000950142-26-001027 · es260758772_4-kaiser.xml · derivative · entry 1 Kaiser Larry · CIK 0002048184 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 25,000 Underlying: Common Shares · 25,000 shares Expires 2031-03-27 Read SEC document |
| December 16, 2025 Filed Dec 18, 2025 21:08 UTC | Medicus Pharma Ltd. MDCX · Entity 7770 | GrantStock Option (right to buy) · Derivative | 25,000 | $0.00 Strike: $1.80 | $0.00 |
DisclosureSEC source: 0000950142-25-003235 · es250717265_4-kaiser.xml · derivative · entry 1 Kaiser Larry · CIK 0002048184 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 25,000 Underlying: Common Shares · 25,000 shares Expires 2030-12-16 F1 · derivative.exercise_date: The option was granted on December 16, 2025. The option is scheduled to vest quarterly in four equal installments over one year. Read SEC document |
| July 22, 2025 Filed Jul 24, 2025 21:15 UTC | Medicus Pharma Ltd. MDCX · Entity 7770 | GrantStock Option (right to buy) · Derivative | 25,000 | $0.00 Strike: $3.08 | $0.00 |
DisclosureSEC source: 0000950142-25-002016 · es250658441_4-kaiser.xml · derivative · entry 2 Kaiser Larry · CIK 0002048184 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 25,000 Underlying: Common Shares · 25,000 shares Expires 2030-07-22 F3 · derivative.exercise_date: The option was granted on July 22, 2025. The option is scheduled to vest quarterly in four equal installments over one year. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.